【摘要】 目的:探讨阿托伐他汀不同剂量和疗程对老年急性冠脉综合征(ACS)患者血浆可溶性细胞间粘附分子-1(sICAM-1)和可溶性E-选择素(sE-selectin)表达的影响。方法:选择ACS患者124例,随机分为3组,阿托伐他汀高剂量组(A组)、低剂量组(B组)和对照组(C组),A组和B组口服阿托伐他汀分别为20 mg/d和10mg/d,C组不服用他汀类药物,用酶联免疫吸附测定(ELISA)法分别测定3组患者治疗前,治疗4周、8周和24周后血浆sICAM和sE-选择素的浓度。结果:A组和B组患者治疗4周、8周和16周后sICAM和sE-选择素水平呈逐渐降低趋势,同治疗前比较差异均有显著性(P<0.05,<0.05,<0.01),C组治疗前、后差异无显著性(P>0.05);A组8周和24周时sICAM和sE-选择素较B组显著降低(P均<0.05)结论:阿托伐他汀具有抑制细胞粘附分子表达的作用,其作用可能与剂量和疗程有关,随剂量增加和应用时间延长而作用增强。更多还原

【Abstract】 Objective:To explore the effects of atorvastatin in different dosage and stage on expression of plasma soluble ICAM-1(sICAM-1) and soluble E-selectin(sE-selectin) in old patients with acute coronary syndrome(ACS).Methods:A total of 124 patients with ACS were randomly divided into three groups including atorvastatin in high dosage group(group A),atorvastatin in low dosage group(group B) and control group(group C).Patients in group A and B were respectively treated with atorvastatin 20 mg and l0 mg per day for 24 weeks.Before and after treated 4,8 and 24 weeks,the concentrations of plasma sICAM-1 and sE-selectin were measured by ELISA.Results:After 4,8 and 24 weeks of treatment,the levels of plasma sICAM-1 and sE-selectin significantly reduced than before(P<0.05,<0.05,<0.01) in group A and B,and there was a tendency of reduced concentrations,but in group C the difference was no statistic significance(P>0.05).After 8 and 24 weeks of treatment,the concentrations of sICAM-1 and sE-selectin in group A patients were lower than that in group B(P<0.05).Conclusion:Atorvastatin can inhibit expression of cell adhesion molecule,which is related with dosage and stage.更多还原